Literature DB >> 26192120

Comparison between α-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model.

Jianqing Lu1, Feiyi Sun1, Hong Ma1, Hong Qing1, Yulin Deng2.   

Abstract

BACKGROUND AND AIMS: Vector based over-expression of α-synuclein is a newly developed method to establish animal Parkinson's disease (PD) model. In this paper, we inject the rat brain with recombinant adeno-associated virus (rAAV) to express α-synuclein wild-type and A53T mutation, and compared the degeneration of dopaminergic neurons between them. METHOD AND
RESULTS: The rAAV vectors were injected into the substantia nigra pars compacta (SNpc) of rat brain. In different time point, immunohistochemistry was used to detect the expression of α-synuclein. The expression level was lower in the 3rd and 6th week and increased from the 9th week. α-synuclein spread around the neurons in SNpc in the 12th week. The loss of dopaminergic neurons was increasing along the expression of α-synuclein, and damage extent was more serious in the A53T group than the WT group. In the A53T group, there were more insoluble inclusions can be detected, and the phosphorylation of α-synuclein was also higher. CONLUSION: The result of comparison between the two types of α-synuclein showed that A53T mutated α-synuclein was more effective to establish PD model, and the model based A53T mutated α-synuclein was a suitable model to early-onset PD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Parkinson's disease; Recombinant adeno-associated virus; α-synuclein

Mesh:

Substances:

Year:  2015        PMID: 26192120     DOI: 10.1016/j.bbrc.2015.07.007

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Elevated Hapln2 Expression Contributes to Protein Aggregation and Neurodegeneration in an Animal Model of Parkinson's Disease.

Authors:  Qinqin Wang; Qinbo Zhou; Shuzhen Zhang; Wei Shao; Yanqing Yin; Yandong Li; Jincan Hou; Xinhua Zhang; Yongshun Guo; Xiaomin Wang; Xiaosong Gu; Jiawei Zhou
Journal:  Front Aging Neurosci       Date:  2016-08-23       Impact factor: 5.750

2.  Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson's disease alpha-synuclein transgenic mice.

Authors:  Minsook Ye; Hwan-Suck Chung; Chanju Lee; Joo Hyun Song; Insop Shim; Youn-Sub Kim; Hyunsu Bae
Journal:  Exp Mol Med       Date:  2016-07-08       Impact factor: 8.718

3.  MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation.

Authors:  Seongmi Lee; Seung Tack Oh; Ha Jin Jeong; Sok Cheon Pak; Hi-Joon Park; Jongpil Kim; Hyun-Seok Cho; Songhee Jeon
Journal:  Korean J Physiol Pharmacol       Date:  2017-10-30       Impact factor: 2.016

4.  Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death.

Authors:  Ana I Rodriguez-Perez; Diego Sucunza; Maria A Pedrosa; Pablo Garrido-Gil; Jaime Kulisevsky; Jose L Lanciego; Jose L Labandeira-Garcia
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Ethanol extract from Gynostemma pentaphyllum ameliorates dopaminergic neuronal cell death in transgenic mice expressing mutant A53T human alpha-synuclein.

Authors:  Hyun Jin Park; Ting Ting Zhao; Seung Hwan Kim; Chong Kil Lee; Bang Yeon Hwang; Kyung Eun Lee; Myung Koo Lee
Journal:  Neural Regen Res       Date:  2020-02       Impact factor: 5.135

Review 6.  Modeling Parkinson's Disease With the Alpha-Synuclein Protein.

Authors:  Mónica Gómez-Benito; Noelia Granado; Patricia García-Sanz; Anne Michel; Mireille Dumoulin; Rosario Moratalla
Journal:  Front Pharmacol       Date:  2020-04-23       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.